Verastem, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 28/100
What the filing says
Verastem amended and restated its 2021 Equity Incentive Plan (16.75M shares available) and 2018 Employee Stock Purchase Plan (5.03M shares available). Concretely: Q2 2026 net product revenue of $25.1M (vs. $2.1M in Q2 2025); company received $15M milestone from Secura Bio on COPIKTRA sales; secured $50M immediate cash from Oberland Capital royalty financing (up to $75M total). Cash position of $136.4M as of June 30, 2026; proforma $201.4M including Oberland and milestone. Company expects cash runway into H2 2027.
Why this rating
Plan amendments are routine governance. Revenue growth and $50M financing are material positives, but company remains unprofitable (Q2 loss $34.7M) with substantial R&D burn. Financing extends runway but represents smaller fraction of $254M market cap.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.